s6y

BridgeBio Oncology Therapeutics, Inc.

Ticker
BBOT
CIK
1869105
Industry
Pharmaceutical Preparations
Formerly
Helix Acquisition Corp. II

Financials 11

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-K Annual Report for period ending Dec 31, 2025
  5. 10-Q Quarterly Report for period ending Sep 30, 2025
  6. 10-Q Quarterly Report for period ending Jun 30, 2025
  7. 10-Q Quarterly Report for period ending Mar 31, 2025
  8. 10-K Annual Report for period ending Dec 31, 2024
  9. 10-Q Quarterly Report for period ending Sep 30, 2024
  10. 10-Q Quarterly Report for period ending Jun 30, 2024

All 11 financials filings

News 21

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 21 news filings

Ownership 77

  1. 4 Statement of changes in beneficial ownership of securities
  2. 4 Statement of changes in beneficial ownership of securities
  3. 4 Statement of changes in beneficial ownership of securities
  4. 4 Statement of changes in beneficial ownership of securities
  5. 4 Statement of changes in beneficial ownership of securities
  6. 4 Statement of changes in beneficial ownership of securities
  7. 4 Statement of changes in beneficial ownership of securities
  8. 4 Statement of changes in beneficial ownership of securities
  9. 4 Statement of changes in beneficial ownership of securities
  10. 4 Statement of changes in beneficial ownership of securities

All 77 ownership filings

Prospectus 36

  1. S-3 Registration statement for specified transactions by certain issuers
  2. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  3. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  4. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  5. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  6. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  7. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  8. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  9. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  10. 424B3 Prospectus filed pursuant to Rule 424(b)(3)

All 36 prospectus filings

Proxies 2

  1. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  2. DEF 14A Definitive proxy statements

Other 44

  1. 144 Filing for proposed sale of securities under Rule 144
  2. 144 Filing for proposed sale of securities under Rule 144
  3. SCHEDULE 13G/A
  4. EFFECT Notice of Effectiveness
  5. EFFECT Notice of Effectiveness
  6. POS AM Post-effective amendment to a registration statement that is not immediately effective upon filing
  7. SCHEDULE 13D/A
  8. EFFECT Notice of Effectiveness
  9. POS AM Post-effective amendment to a registration statement that is not immediately effective upon filing
  10. ARS Annual report to security holders

All 44 other filings